Japan Deeping Debate on LLP Copay Review; Focus Is on Exclusion Criteria, Payment Levels, G1/G2 Rule Change

Chuikyo General Assembly Meeting on Nov. 24 Japan’s all-important reimbursement policy panel has started detailed discussions on the proposed copay review of off-patent brand-name drugs, called long-listed products (LLPs), which would require additional out-of-pocket payments for patients who use these...read more